Resurrect Bio, a biotechnology company developing disease-resistant crops through gene editing, announced the final close of its Series A funding round at $10.3 million, oversubscribed from the company’s previously announced $8.1 million initial close in February 2026.
The round was led by Corteva through its Corteva Catalyst platform, with participation from Calculus Capital, Pymwymic, Future Planet Capital through UKI2S, SynBioVen, and AgFunder. The final close brings Resurrect Bio’s total capital raised to approximately $12.4 million since its founding, including its 2023 seed round.
The company said the oversubscribed financing reflects growing confidence in its approach to developing sustainable, gene-edited disease resistance for crops. Momentum around the round follows Resurrect Bio’s joint development agreement with Corteva announced in March 2026 to develop disease resistance in corn.
Resurrect Bio plans to use the funding to scale its FloraFold AI in-silico discovery platform, expand its high-throughput functional biology platform, and further develop its Resurrection platform, which reactivates cryptic resistance mechanisms already present in elite crop germplasm. The company said these technologies help compress the timeline from crop trait discovery to deployment.
With the new capital, Resurrect Bio said it is preparing to engage seed companies and breeders through additional joint development agreements aimed at bringing durable disease-resistance traits into commercial pipelines faster than conventional breeding approaches.
Founded as a spinout from The Sainsbury Laboratory, Resurrect Bio was established by Sophien Kamoun, Tolga Bozkurt, and Cian Duggan.
KEY QUOTES:
“We’re proud to have closed this round with such a distinguished and strategically aligned group of partners. The strength of this raise reflects growing conviction in what we’re building: a scalable, AI-driven platform for resurrecting disease resistance in the world’s most important crops. It’s also a validation of what’s possible when you combine the UK’s world-class plant science base with commercial ambition to translate it into real-world impact. We’re expanding our team, deepening our platforms, and actively seeking joint development agreements with seed companies and breeders who want to bring durable resistance traits to farmers.”
Dr. Cian Duggan, CEO, Resurrect Bio
“We’re delighted to join this strong syndicate backing Resurrect Bio. Crop disease remains a major and often overlooked challenge in global agriculture. Resurrect Bio’s innovative gene-editing platform, which restores native disease-resistance genes in crops, offers a promising solution by reducing dependence on chemicals and boosting yields. The team has built an impressive AI-driven platform that places them at the forefront of a new wave of agricultural innovation. We look forward to supporting their continued progress as they work with partners across the industry to develop more resilient crops.”
Elizabeth Klein-Edmonds, Investment Director, Calculus Capital
